Brief: Strides Pharma Science Says Completion Of US-FDA Inspection At Co's USA Facility
24/12/2025 13:12
Dec 24 (Reuters) - Strides Pharma Science Ltd SRID.NS: COMPLETION OF US-FDA INSPECTION AT STRIDES PHARMA USA FACILITY FDA ISSUES FORM 483 WITH FOUR PROCEDURAL OBSERVATIONS Source text: ID:nNSE5ZWygH Further company coverage: SRID.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees